Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway
PDF | HTML | How to cite
Metrics: PDF 1800 views | HTML 2355 views | ?
Ning Tang1,*, Lei Shi2,*, Zhenlong Yu1,4,*, Peipei Dong1, Chao Wang1, Xiaokui Huo1, Baojing Zhang1, Shanshan Huang1, Sa Deng1, Kexin Liu1, Tonghui Ma3, Xiaobo Wang4, Lijun Wu4, Xiao-Chi Ma1,4
1College of Pharmacy, Academy of Integrative Medicine, Key Laboratory of Pharmacokinetic and Drug Transport of Liaoning, Dalian Medical University, Dalian, China
2Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China
3College of Basic Medical Science, Dalian Medical University, Dalian, China
4Department of Pharmacy and Traditional Chinese medicine, Chinese People’s Liberation Army 210 Hospital, Dalian, China
*These authors have contributed equally to this work
Xiao-Chi Ma, e-mail: [email protected]
Keywords: gamabufotalin, angiogenesis, vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 2 (VEGFR-2), aortic ring
Received: August 18, 2015 Accepted: November 21, 2015 Published: December 09, 2015
Gamabufotalin (CS-6), a main active compound isolated from Chinese medicine Chansu, has been shown to strongly inhibit cancer cell growth and inflammatory response. However, its effects on angiogenesis have not been known yet. Here, we sought to determine the biological effects of CS-6 on signaling mechanisms during angiogenesis. Our present results fully demonstrate that CS-6 could significantly inhibit VEGF triggered HUVECs proliferation, migration, invasion and tubulogenesis in vitro and blocked vascularization in Matrigel plugs impregnated in C57/BL6 mice as well as reduced vessel density in human lung tumor xenograft implanted in nude mice. Computer simulations revealed that CS-6 interacted with the ATP-binding sites of VEGFR-2 using molecular docking. Furthermore, western blot analysis indicated that CS-6 inhibited VEGF-induced phosphorylation of VEGFR-2 kinase and suppressed the activity of VEGFR-2-mediated signaling cascades. Therefore, our studies demonstrated that CS-6 inhibited angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways and CS-6 could be a potential candidate in angiogenesis-related disease therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.